




Fig. 1

Female Survival Curve






Fig. 2

**Fig. 3**

Survival of Female lifespan exp start feb 12 2018

**Fig. 4**




Fig. 5

Survival by males and females




Fig. 6





Fig. 7



**** p<.05**

Fig. 8




Fig. 9




Fig. 10A

	Control	AKG	D3	AKG + D3
Control				
AKG	.56			
D3	.04	.08		
AKG + D3	.10	.18	.64	

Fig. 10B




Fig. 10C




Fig. 11A



Fig. 11B




Fig. 12




Fig. 13




Fig. 14




Fig. 15




Fig. 16

ESTIMATES FOR EXTENSION WITH AKG

Ext. from Birth – Males	4%
Ext. from Treat. – Males	10%
Ext. from Birth – Females	7%
Ext. from Treat. – Females	17%
Frailty from Birth – Females	17%
Frailty from Treat. – Females	67%

Fig. 17




Fig. 18




Fig. 19




Fig. 20




Fig. 21




Fig. 22




Fig. 23

	Control	18 months	AKG
IL-1B (25)	1	0.138377364	0.084663547
IL-3 (29)	1	0.143295803	0.399181167
IL-6 (34)	1	0.22415138	0.403639631
TNF α (77)	1	0.238638	1.949896818
GM-CSF (15)	1	0.242947471	0.1523983
IL-10 (43)	1	0.257850051	0.291660694
IL-4 (28)	1	0.27196019	0.315880571
MIP-1B (66)	1	0.27858165	0.468324709
IL-12 (p40) (45)	1	0.320694229	0.393676763
RANTES (75)	1	0.34192489	0.379757016
IL-13 (52)	1	0.346204936	0.272643758
IL-12 (p70) (47)	1	0.384006526	0.056001268
MIG (74)	1	0.397397745	0.912610758
MCP-1 (62)	1	0.434987489	2.101009107
IL-2 (26)	1	0.472699636	0.471634431
G-CSF (13)	1	0.477806673	0.611104914
IP-10 (57)	1	0.533134369	1.154954894
IL-17 (56)	1	0.558234765	0.29197428
MIP-1 α (64)	1	0.560436064	0.375407525
IFN γ (19)	1	0.645812311	0.109149008
VEGF (76)	1	0.693848355	0.683834049
IL-1 α (21)	1	0.70493983	0.544236274
IL-5 (30)	1	0.722142295	0.746495499
KC (61)	1	0.736553481	0.835952196
M-CSF (67)	1	0.825671362	0.678925821
IL-9 (38)	1	0.849248123	1.316876102
Eotaxin (14)	1	0.936693809	0.813662791
MIP-2 (73)	1	0.952643192	0.856532802
IL-7 (36)	1	1.747958564	0.27716291
IL-15 (54)	1	2.294537673	0.383101541
LIX (53)	1	3.189811015	1.556389501

Fig. 24





Fig. 25



* p < .1
** p < .05

Fig. 26

Frailty Combined






Fig. 27



* $p < .1$

** $p < .05$

Fig. 28



* p<.1

Fig. 29




Fig. 30

19/22




Fig. 31






Fig. 32



* p<.05

Fig. 33



P values	Control	AKG	RP	D3
Control				
AKG	.21			
RP	.15	.85		
D3	.04	.50	.63	

Fig. 34




Fig. 35




Fig. 36




Fig. 37